Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 81Thoracic 5Other solid neoplasm 4Tumor-Agnostic 3Head & Neck 3Gynecologic 1Genitourinary 1Breast 1

Conditions

Neoplasms 2Adenocarcinoma 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × S 1 (combination) × Tumor-Agnostic × Clear all
NCT00400023 2024-09-03

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT02564367 2021-04-29

S-1 adjuvant

AIO-Studien-gGmbH

Phase 1/2 Completed
30 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT00479076 2011-01-26

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Sanofi

Phase 1 Completed
22 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡